Born-Impact-6339

the privacy angle is the one that sold me. running genomic analysis on dna data — theres no way im sending that to an external api if i can avoid it. ollama with a local model means zero network calls for the actual analysis. the quality tradeoff is real vs cloud models but for anything involving personal health data its worth it

great question — happy to go into more detail. feel free to DM me or check the writeup at helixsequencing.com/journal where i go into the technical side of everything.

great question — happy to go into more detail. feel free to DM me or check the writeup at helixsequencing.com/journal where i go into the technical side of everything.

Really fair question. You're right that the database lookups themselves are deterministic — you could absolutely do rsID matching against ClinVar with a simple SQL query and skip the LLM entirely for that part. The value the LLM adds is in three areas: 1. **Cross-domain reasoning** — when the pharma agent finds a DPYD variant and the cancer agent independently finds a BRCA2 variant, a human geneticist would immediately connect those (DPYD affects fluoropyrimidine metabolism which matters for chemo). An LLM can make that same leap. A rule-based system would need you to pre-program every possible cross-domain connection. 2. **Narrative synthesis** — the final report isn't just a list of variants. It contextualizes findings for the patient, explains what compound patterns mean, and prioritizes what matters. That's genuinely hard to template. 3. **Flexible queries** — agents can ask follow-up questions based on what they find. If they see an unexpected variant, they can query additional databases or change their search strategy. A static pipeline can't adapt. That said, you could definitely build a hybrid where the DB lookups are deterministic and only the synthesis/reporting uses an LLM. Would probably be faster and cheaper. Something we might explore.

Good question — this was actually one of the trickiest parts to get right. The main mechanism is the `publish_finding` tool which does keyword-overlap deduplication before anything gets added to the shared findings board. So if two agents both find the same BRCA2 variant, the second one gets blocked from publishing a duplicate. For interpretation conflicts (like one agent calling something pathogenic and another calling it uncertain), we intentionally let both through to the synthesizer. The synthesizer agent's entire job is resolving those conflicts — it sees all findings from all agents and weighs the evidence. In practice, conflicts usually come from agents looking at different databases (e.g. ClinVar says pathogenic but AlphaMissense says benign), and the synthesizer is pretty good at noting the discrepancy and explaining why. The chatroom also helps — agents can send urgent messages to flag things. So if the cancer agent finds something concerning, it doesn't just publish, it also pings the relevant agents directly with context. This prevents the "two ships passing in the night" problem.